FDA Approves First Blood Test for Alzheimer’s Diagnosis

1. FDA Approves First Blood Test to Help Diagnose Alzheimer’s Disease

The U.S. Food and Drug Administration has approved the first blood-based test that can aid in diagnosing Alzheimer’s disease in patients aged 55 and older.

The test measures β-amyloid levels in the blood, offering a simpler alternative to PET scans or cerebrospinal fluid (CSF) testing.

👉 This marks a breakthrough in early detection and could make diagnosis more accessible.

Source: AP News

2. FDA Approves Subcutaneous Version of Merck’s KEYTRUDA (pembrolizumab)

Merck announced FDA approval of KEYTRUDA QLEX™ (pembrolizumab + berahyaluronidase alfa-pmph) for subcutaneous (under the skin) injection in adults across most solid tumor indications.
This new formulation significantly reduces administration time compared to IV infusion, improving patient convenience.
Source: Merck

3. FDA 2025 Novel Drug Approvals – New Options for Patients

The FDA’s 2025 list of novel drug approvals includes:
-Anzupgo (delgocitinib): For chronic hand eczema in patients unresponsive to topical corticosteroids.
-Palsonify (paltusotine): For acromegaly, offering an oral alternative to existing injectable therapies.
These approvals expand treatment options in dermatology and endocrinology.
Source: FDA.gov

⚠️ Disclaimer: This content is for educational purposes only. Always consult healthcare professionals for diagnosis and treatment decisions.